FNA vs. SILK, ATRI, AORT, KIDS, TMCI, MDXG, SIBN, EMBC, IRMD, and OFIX
Should you be buying Paragon 28 stock or one of its competitors? The main competitors of Paragon 28 include Silk Road Medical (SILK), Atrion (ATRI), Artivion (AORT), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), MiMedx Group (MDXG), SI-BONE (SIBN), Embecta (EMBC), Iradimed (IRMD), and Orthofix Medical (OFIX). These companies are all part of the "surgical & medical instruments" industry.
Paragon 28 (NYSE:FNA) and Silk Road Medical (NASDAQ:SILK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk.
Paragon 28 has higher revenue and earnings than Silk Road Medical. Paragon 28 is trading at a lower price-to-earnings ratio than Silk Road Medical, indicating that it is currently the more affordable of the two stocks.
Paragon 28 has a net margin of -22.11% compared to Silk Road Medical's net margin of -29.02%. Paragon 28's return on equity of -22.51% beat Silk Road Medical's return on equity.
Silk Road Medical received 64 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 78.79% of users gave Paragon 28 an outperform vote while only 50.56% of users gave Silk Road Medical an outperform vote.
63.6% of Paragon 28 shares are held by institutional investors. 15.3% of Paragon 28 shares are held by company insiders. Comparatively, 6.7% of Silk Road Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Silk Road Medical had 19 more articles in the media than Paragon 28. MarketBeat recorded 21 mentions for Silk Road Medical and 2 mentions for Paragon 28. Silk Road Medical's average media sentiment score of 0.53 beat Paragon 28's score of 0.00 indicating that Silk Road Medical is being referred to more favorably in the news media.
Paragon 28 currently has a consensus price target of $17.67, indicating a potential upside of 65.26%. Silk Road Medical has a consensus price target of $22.55, indicating a potential upside of 10.35%. Given Paragon 28's stronger consensus rating and higher possible upside, research analysts plainly believe Paragon 28 is more favorable than Silk Road Medical.
Paragon 28 has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.
Summary
Paragon 28 beats Silk Road Medical on 11 of the 17 factors compared between the two stocks.
Get Paragon 28 News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Paragon 28 Competitors List
Related Companies and Tools
